The Ministry of Health received Tuesday 100,000 doses of the AstraZeneca vaccine and 100,000 Covid-19 test kits from Hungary. - VnExpress International
Vietnam s Covid-19 vaccine completes 50% of phase 2 trial Chia sẻ | FaceBookTwitter Email Copy Link Copy link bài viết thành công
12/03/2021 09:25 GMT+7
Vietnam has completed the first-dose vaccination of 560 volunteers who participated in the Phase 2 trial of Nanocovax s Covid-19 vaccine,
Dr. Chu Van Men, Director of the Center for Clinical Trials and Bioequivalence at the Military Medical Academy, has told VietNamNet.
A volunteer participated in the second phase trial of Nanocovax vaccine at the Military Medical Academy on February 26. Photo: Thuy Hanh
In phase 2, Nanocovax vaccine was tested simultaneously at the Military Medical Academy and the Medical Center in southern province of Long An by the HCM City Pasteur Institute, with the participation of 280 volunteers at each site.
THREE first volunteers have received the first shots of a dose of 50mcg of Nanocovax Covid-19 vaccine.
Developed by the Nanogen Pharmaceutical Biotechnology JSC and the Vietnam Military Medical University, Nanocovax is Vietnam’s first Covid-19 candidate vaccine to reach the human trial stage.
A total of 60 volunteers, aged 18 to 50, were selected for the first phase of clinical trials.
They were divided into three groups receiving three doses of 25mcg, 50mcg and 75mcg respectively. The vaccination consists of two injections 28 days apart.
After the injection, the volunteers were put under health monitoring at the Hanoi-based Military Medical University for 72 hours.
By VNA / DA NANG Today
December 27, 2020, 10:07 [GMT+7]
Three first volunteers received the first shot of a dose of 50mcg of Nanocovax Covid-19 vaccine on December 26 morning.
One of the three first volunteers receiving first shots of 50mcg dose of Covid-19 vaccine (Photo: VNA)
Developed by the Nanogen Pharmaceutical Biotechnology JSC and the Vietnam Military Medical University, Nanocovax is Vietnam s first Covid-19 candidate vaccine to reach the human trial stage.
A total of 60 volunteers, aged 18-50, were selected for the first phase of the clinical trials. They are divided into three groups for receiving three doses of 25 mcg, 50 mcg and 75 mcg, respectively. The vaccination consists of two injections 28 days apart.